See the DrugPatentWatch profile for Amvuttra
Amvuttra is a medication used to treat transthyretin amyloidosis, a rare disease that can cause progressive damage to nerves and organs. It is a selective tafamidis formulation. [1]
What type of drug is Amvuttra?
Amvuttra is a transthyretin stabilizer. It works by binding to transthyretin (TTR) and preventing it from misfolding and forming amyloid deposits in tissues. [1]
How does Amvuttra work in treating transthyretin amyloidosis?
Transthyretin amyloidosis (ATTR) is caused by the misfolding of TTR protein, which then forms amyloid fibrils that deposit in various organs, leading to progressive damage. Amvuttra stabilizes the TTR protein in its normal, folded state, thereby reducing the formation of these harmful amyloid deposits. [1]
What is the active ingredient in Amvuttra?
The active ingredient in Amvuttra is tafamidis. [1]
Who makes Amvuttra?
Amvuttra is manufactured by Pfizer. [1]
When was Amvuttra approved?
Amvuttra received FDA approval on February 13, 2023, for the treatment of transthyretin amyloidosis. [1]
What is the difference between Amvuttra and Vyndaqel/Vyndamax?
Both Amvuttra and Vyndaqel/Vyndamax (which also contain tafamidis) are used to treat transthyretin amyloidosis. Amvuttra is a new formulation of tafamidis. While both target TTR stabilization, specific formulation differences may exist. [1]
What are the side effects of Amvuttra?
The most common side effects reported in clinical trials for Amvuttra include diarrhea, muscle spasms, and upper respiratory tract infections. [1]
How is Amvuttra administered?
Amvuttra is taken orally. [1]
What is the dosage for Amvuttra?
The recommended dosage for Amvuttra is 2 grams taken orally once daily. [1]
What clinical trials were conducted for Amvuttra?
Amvuttra's approval was based on data from clinical studies, including the ATTRibute-CM study. [1]
What is transthyretin amyloidosis (ATTR)?
Transthyretin amyloidosis is a progressive and life-threatening disease that occurs when TTR protein deposits as amyloid in nerves and organs. It can manifest in different forms, including polyneuropathy (ATTR-PN) and cardiomyopathy (ATTR-CM). [1]
What is the prognosis for patients with transthyretin amyloidosis?
ATTR is a serious condition that can lead to significant organ damage and reduced life expectancy if left untreated. Treatment aims to slow disease progression and manage symptoms. [1]
Are there other treatments for transthyretin amyloidosis?
Other treatment options for transthyretin amyloidosis include other tafamidis formulations and gene silencing therapies. [1]
Does Amvuttra have patent protection?
Information regarding specific patent details for Amvuttra can be found on DrugPatentWatch.com. [2]
How does Amvuttra compare to gene silencing therapies for ATTR?
Gene silencing therapies work by reducing the production of the TTR protein itself, whereas Amvuttra stabilizes the existing TTR protein. [1]
Can Amvuttra be used for both ATTR-PN and ATTR-CM?
Amvuttra is indicated for the treatment of transthyretin amyloidosis. [1]
---
Sources:
1. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-us-food-and-drug-administration-fda-approval
2. https://drugpatentwatch.com/